Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The Japan tuberculosis treatment market was valued at USD 466.57 Million in 2025, driven by the increasing incidence of tuberculosis in the region. The market is anticipated to grow at a CAGR of 4.80% during the forecast period of 2026-2035, with the values likely to reach USD 745.64 Million by 2035.
Q1 2026 Market Updates
The Iran-US-Israel conflict that escalated on February 28, 2026, is adding complexity to the Japan tuberculosis treatment market, valued at approximately USD 512.2 million in 2025 and projected to grow at a CAGR of 5.65% through 2032. The near-total closure of the Strait of Hormuz and the 79% drop in Gulf region air-cargo capacity have disrupted pharmaceutical logistics corridors critical for TB drug supply chains. Japan's pharmaceutical trade group has urged government intervention, including chartered cargo flights, to maintain medicine supplies as the conflict enters its second month.
Japan's aging population - the primary driver of TB treatment demand - is particularly susceptible to tuberculosis due to weakened immunity, making uninterrupted access to therapeutic drugs a public health imperative. Active TB treatment requires multi-drug regimens administered over extended periods, and any disruption in supply of first-line medications such as isoniazid, rifampicin, and ethambutol could compromise patient outcomes. The conflict has pushed raw material prices for pharmaceutical compounds up between 5 and 100 percent, while active ingredients containing petroleum-derived key starting materials now cost more and take longer to reach Japanese manufacturers.
Leading market participants including Pfizer, Novartis, Merck, and Japan-based Otsuka Pharmaceutical - developer of the innovative anti-TB drug Deltyba (delamanid) for multidrug-resistant TB - face elevated input and logistics costs. Maritime insurance premiums for Strait of Hormuz transit have surged over 1,000%, and air cargo rates from Asia have risen 200-350% on some routes. These cost increases are particularly concerning for TB treatment programs that serve vulnerable elderly populations and require affordable, sustained medication access.
While short-term drug shortages remain unlikely due to existing inventory buffers, the conflict highlights the fragility of Japan's pharmaceutical import dependencies. Strengthening domestic production of critical TB medications and diversifying supply routes away from Gulf corridors are becoming strategic priorities for ensuring continued treatment access.
Key Takeaways
Government: Japanese health authorities should establish strategic reserves of essential TB medications and support domestic production of first-line drugs to reduce dependence on disrupted Gulf logistics corridors. Expediting regulatory pathways for alternative drug suppliers and maintaining chartered pharmaceutical cargo services are critical for protecting elderly TB patients from treatment interruptions.
Market: The Japan TB treatment market faces rising input costs from pharmaceutical raw material price surges and elevated logistics expenses. Manufacturers like Otsuka Pharmaceutical must manage margin pressures while sustaining innovation in multidrug-resistant TB therapies, as the conflict-driven cost environment threatens the affordability of extended treatment regimens.
Procurement: Procurement teams should secure advance inventories of multi-drug TB treatment regimens and diversify active pharmaceutical ingredient sourcing beyond Gulf-dependent supply routes. Establishing contracts with multiple suppliers across different geographic regions will help maintain consistent medication availability for Japan's TB treatment programs.
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
-
The primary driver of the market is the expanding aging population in Japan, which is more susceptible to tuberculosis due to weakened immunity, increasing demand for early diagnosis, and long-term therapeutic care.
-
Recent market trends include growing adoption of rapid diagnostic techniques and molecular testing, along with rising government initiatives focused on nationwide tuberculosis screening, treatment adherence, and reducing latent TB infections among high-risk populations.
-
Japan's tuberculosis treatment market benefits from a robust healthcare system, strong pharmaceutical presence, and consistent public health campaigns aimed at improving awareness, early intervention, and access to affordable and effective TB medications.
Compound Annual Growth Rate
4.8%
Value in USD Million
2026-2035
*this image is indicative*
Japan Tuberculosis Treatment Market Overview
Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially impacting other organs. Tuberculosis treatment involves a multi-drug antibiotic regimen over several months to ensure complete eradication and prevent resistance. The Japan tuberculosis treatment market is supported by robust healthcare systems, aging demographics, and national efforts in disease control and prevention.
Japan Tuberculosis Treatment Market Growth Drivers
Rising Tuberculosis Incidence to Accelerate Market Growth
The increasing incidence of tuberculosis is a significant driver of market growth in Japan. As per the World Health Organization, Japan recorded a tuberculosis incidence rate of 9.3 cases per 100,000 population in 2023. This ongoing public health concern reflects the demand for effective therapies, thereby contributing to the expansion of the tuberculosis treatment market.
Japan Tuberculosis Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Japan Tuberculosis Treatment Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Active TB
- Latent TB
Market Breakup by Therapy
- First-Line Therapy
- Second-Line Therapy
Market Breakup by Dosage Form
- Tablets
- Capsules
- Injections
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Japan Tuberculosis Treatment Market Share
Active TB to Dominate the Market Share Based on Disease Type
Based on disease type, the market is divided into active TB and latent TB. Among these, active tuberculosis is expected to hold a significant share of the market, driven by its higher transmission risk, symptomatic nature, and greater need for immediate medical intervention. The growing global burden of active TB cases and increased public health efforts for early detection and treatment further contribute to its dominant share in the tuberculosis treatment market.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Japan Tuberculosis Treatment Market Analysis by Region
The Japan tuberculosis treatment market shows strong regional performance, with the eastern and western regions leading due to their dense populations and well-established healthcare systems. Eastern Japan, including Tokyo and surrounding areas, drives demand through advanced medical facilities. Western Japan, particularly Osaka, contributes significantly through ongoing public health initiatives and increased awareness of tuberculosis screening and treatment.
Leading Players in the Japan Tuberculosis Treatment Market
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi
Sanofi, established in 1973 and headquartered in Paris, France, is a global healthcare leader committed to developing innovative treatments. In the tuberculosis treatment market, Sanofi plays a significant role through its product Priftin® (rifapentine), used in combination with isoniazid for latent tuberculosis infection. The company’s long-standing investment in tuberculosis research strengthens its impact in the region.
Johnson and Johnson Services Inc.
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson Services Inc. plays a significant role in tuberculosis treatment through its product Sirturo (bedaquiline). Approved by the U.S. FDA and European Commission in July 2024, SIRTURO® is vital for treating multidrug-resistant tuberculosis and supports global treatment protocols, including those adopted in Japan.
Otsuka Pharmaceutical, Inc.
Otsuka Pharmaceutical Co., Ltd., established in 1964 and headquartered in Tokyo, Japan, is a global healthcare company actively involved in tuberculosis treatment. The company has developed Deltyba (delamanid), an innovative anti-tuberculosis drug used to treat multidrug-resistant TB. Through its research and development efforts, Otsuka continues to address critical needs in the tuberculosis treatment market.
GlaxoSmithKline plc
GlaxoSmithKline plc, headquartered in London, United Kingdom, plays a key role in tuberculosis treatment. The company joined the PAN-TB collaboration, a global initiative aimed at developing novel, simplified, and resistance-free tuberculosis regimens. This strategic involvement supports innovation in Japan's TB treatment market, addressing complex treatment challenges and drug-resistant cases.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, and Eli Lilly and Company.
Key Questions Answered in the Japan Tuberculosis Treatment Market Report
- What was the Japan tuberculosis treatment market value in 2025?
- What is the Japan tuberculosis treatment market forecast outlook for 2026-2035?
- What is the market segmentation based on disease type?
- What is the market breakup based on the therapy?
- What is the market breakup based on the dosage form?
- How is the market segmented based on route of administration?
- How is the market divided based on the end user?
- What are the major factors aiding the Japan tuberculosis treatment market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Japan tuberculosis treatment market trends?
- Which disease type is expected to dominate the market segment?
- Which therapy is expected to dominate the market segment?
- Which dosage form is projected to lead the market segment?
- Which route of administration is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players involved in the Japan tuberculosis treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Therapy |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share